Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration gmbh - mycophenolate mofetil - rifjut ta 'graft - immunosoppressanti - cellcept huwa indikat flimkien ma 'ciclosporin u kortikosterojdi għall-profilassi ta' rifjut akut ta 'trapjant f'pazjenti li qed jirċievu trapjanti alloġeniċi renali, tal-qalb jew tal-fwied.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v. - telaprevir - epatite Ċ, kronika - antivirali għal użu sistemiku - incivo, f'kombinazzjoni ma 'peginterferon alfa u ribavirin, huwa indikat għall-kura tal-ġenotip-1 epatite Ċ kronika f'pazjenti adulti b'mard kumpensat tal-fwied (inkluż ċirrożi):li huma trattament naïve;li jkunu diġà ġew ittrattati b'interferon alfa (pegylated jew mhux pegylated) waħdu jew f'kombinazzjoni ma' ribavirin, inkluż relapsers, dawk li wrew rispons parzjali u dawk li rrispondew null.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

amarin pharmaceuticals ireland limited - icosapent ethyl - dyslipidemias - aġenti li jimmodifikaw il-lipidi - indicated to reduce cardiovascular risk as an adjunct to statin therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - zoledronic acid - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - drogi għat-trattament ta 'mard tal-għadam - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture, including those with a recent low-trauma hip fracture. trattament ta ' osteoporożi assoċjat ma sistemiku fit-tul terapija bi glukokortikojdi fil-nisa wara l-menopawża u f'irġiel f'riskju akbar ta'ksur. it-trattament tal-marda ta'paget ta ' l-għadam.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - teduglutide - sindromi ta 'malassorbiment - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - revestive huwa indikat għall-kura ta 'pazjenti ta' età ta 'sena u aktar minn sindromu qosra tal-musrana (sbs). il-pazjenti għandhom ikunu stabbli wara perijodu ta 'adattament intestinali wara l-operazzjoni. revestive huwa indikat għall-kura tal-pazjenti ta'bejn l-1 sena u ' l fuq bil-qosor tal-musrana sindromu. il-pazjenti għandhom ikunu stabbli wara perijodu ta 'adattament intestinali wara l-operazzjoni.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibatteriċi għal użu sistemiku, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetes mellitus, tip 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 u 5. 1 għad-data disponibbli dwar kombinazzjonijiet differenti).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

canyon pharmaceuticals ltd. - desirudin - trombożi venuża - aġenti antitrombotiċi - prevenzjoni ta 'trombożi fil-vini fil-fond f'pazjenti li għaddejjin minn kirurġija ta' sostituzzjoni tal-ġenb jew tal-irkoppa elettiva.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - anagrelide - tromboċitemja, essenzjali - aġenti antineoplastiċi - xagrid huwa indikat għat-tnaqqis tal-għadd tal-platelets elevati fil-pazjenti at-risk essenzjali-thrombocythaemia (et) li huma intolerant biex-terapija kurrenti tagħhom jew l-għadd tagħhom platelets elevati ma jiġux imnaqqsa għal livell aċċettabbli mill-terapija kurrenti tagħhom. l-riskju patientan fil-riskju et huwa ddefenit b'waħda jew aktar mill-karatteristiċi li ġejjin:>60 sena ta ' età jew l;għadd tal-plejtlets >1000 x 109/l jew;l-istorja tal-każijiet tromboemorragiċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mylan pharmaceuticals limited - anagrelide hydrochloride - tromboċitemja, essenzjali - aġenti antineoplastiċi - anagrelide huwa indikat għat-tnaqqis tal-għadd għoli tal-plejtlets f'mill-riskju tromboċitemja essenzjali (et) tal-pazjenti li jkunu intolleranti għall it-terapija attwali tagħhom jew li l-għadd għoli tal-plejtlets tagħhom ma jitnaqqasx għal-livell aċċettabbli bit-terapija attwali tagħhom. an at-risk patientan at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events.